Disclosures

1. What Klarovel is (and is not)

Klarovel is a global peptide intelligence platform. We publish research-grade educational content on peptides, protocols, and longevity science. We do not supply peptides, and we do not refer users to anyone who does.

Klarovel is not a pharmacy, not a clinic, not a medical practice, and not a healthcare provider. We do not manufacture, hold, ship, or sell peptides, and we do not broker their sale. There is no shop, no cart, and no order flow on this platform. Where a user obtains a compound, and from whom, is their own arrangement, made without our involvement and without any payment reaching us.

The protocol itself is generated by a deterministic rules engine, not by a chatbot and not by a clinician. The engine evaluates the user's submitted health questionnaire, optional bloodwork, and goal profile against a curated peptide catalogue; it surfaces recommended peptides, doses, cycling, stacking, and monitoring rules; and it logs every decision so the output is reproducible. The same inputs produce the same protocol every time.

2. Who this content is for

Our content is written for an informed, technically literate audience: researchers, clinicians, biohackers, longevity-curious readers, and others who want to understand peptide science at primary-source depth. We assume the reader is capable of judging the relevance and limits of preclinical and clinical data.

We do not write for first-time peptide-curious readers who want a quick answer to "should I take this?" That question is for a qualified clinician with access to the reader's full medical history. Our content is upstream of that conversation: it gives readers the vocabulary, the citation trail, and the mechanistic framing to ask the right questions when they get to a clinician. Treating peptide science as a consumer purchase decision rather than a clinical evaluation is the failure mode we are explicitly built to avoid.

3. Editorial and medical review

Every long-form post is reviewed before publication by the Klarovel Medical Advisory Board, an independent editorial review function inside Klarovel that checks each piece for: claim sourcing against peer-reviewed literature; dose statements against the published peptide research catalogue; regulatory accuracy where the post touches jurisdiction-specific rules; and tone consistent with our wellness-information posture.

Each post carries the date of its most recent review. When regulatory facts, study results, or pricing change materially, the affected post is reviewed again and the review date updated. Pure cosmetic edits (a typo fix, an SEO meta-tag tweak, a non-load-bearing rephrasing) do not bump the review date because the review date is a clinical-vouching signal, not a last-touched timestamp. This distinction matters because Google reads the date as a recency-of-clinical-review marker for medical content, and inflating it would dilute the signal.

4. Sources and citation standards

Every load-bearing factual claim in a Klarovel post carries an inline hyperlink to a primary source. The hierarchy we use, in descending order of weight: peer-reviewed primary literature (PubMed, indexed journals); regulator publications (FDA, EMA, Statens legemiddelverk, MHRA, TGA); recognised guideline bodies (Helsedirektoratet, FHI, NICE, USPSTF, WHO); vendor-neutral authority sites; and finally, where the question is genuinely community-shaped rather than clinical, a small amount of voice-of-customer colour without medical weight.

We do not cite Wikipedia, Reddit, Medium, Substack, YouTube, X threads, or vendor marketing pages as evidence. Vendor pages are sometimes linked for product context (price, formulation, regulatory class) but never as the source for an efficacy or safety claim.

When a claim is genuinely uncertain or the literature is split, we say so. The editorial voice rule is: hedge where the literature hedges; name the gaps where the human data is thin. Posts that pretend to have answers the field does not have are the editorial failure mode we treat as a critical error.

5. How Klarovel makes money

Klarovel is funded by protocol purchases ($99 one time per protocol), and that is the only thing we charge for. We earn no commission, referral fee, or affiliate revenue on any peptide purchase, from any seller, anywhere. There is no distributor network and no preferred supplier. Nothing you buy elsewhere pays us.

Because no seller pays us, nothing commercial can bend the editorial or the engine. A peptide's coverage, its posture in the catalogue, and its dose ceilings are set by the evidence and the safety rules alone. There is no arrangement that could make us soften an unfavourable assessment, because there is no arrangement.

This separation is not a marketing line; it is the legal and operational shape of the platform. Klarovel holds no inventory, handles no fulfilment, and takes no cut of any transaction in which a peptide changes hands.

This disclosure satisfies the United States Federal Trade Commission's 16 CFR Part 255 endorsement guides, the European Union's Unfair Commercial Practices Directive (2005/29/EC), and the Norwegian Forbrukertilsynet's guidance on hidden marketing.

6. No medical advice

Nothing on Klarovel is medical advice, diagnosis, or treatment. Reading our content does not establish any clinician-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or modifying any peptide regimen, especially if you are pregnant, nursing, have a medical condition, or are taking prescription medication.

Specific scenarios where a clinical consult is not optional: active or historical cancer of any kind (most peptides with growth-promoting or angiogenic activity are contraindicated); cardiovascular disease (GH-axis peptides shift fluid balance and may aggravate left-ventricular load); type 1 or insulin- dependent type 2 diabetes alongside any GLP-1 class consideration (hypoglycaemia risk from concomitant insulin or sulfonylureas); pregnancy, lactation, or actively trying to conceive (most peptides are unstudied or contraindicated); and any active psychiatric care, particularly involving serotonergic agents (overlap with serotonergic peptides like Selank or Semax).

A Klarovel protocol is not a substitute for that consult. It is a structured document the reader can bring to a qualified clinician for clinical sign-off before any in-vivo use.

7. Research purposes only

Everything Klarovel publishes about peptides, including every generated protocol, is for research and educational purposes only. Klarovel does not supply peptides and does not direct, supervise, or endorse any in vivo human use. Local laws on the possession, importation, and use of peptides vary widely by jurisdiction; readers are responsible for understanding and complying with the rules that apply where they live.

Specific jurisdictional notes that change the analysis: in the United States, BPC-157 and several other compounds are excluded from compounding pharmacies under FDA's 503A/503B bulks lists, which restricts but does not eliminate research supply; in the European Union, peptides without a marketing authorisation cannot be supplied for human medical use, though research-use supply varies by member state; in Australia, the TGA has issued a standing safety alert on imported unapproved peptides; in Norway, Statens legemiddelverk treats peptides without a marketing authorisation as unapproved medicinal products and customs may intercept personal-import shipments. None of these notes constitutes legal advice and all are subject to revision.

8. What we do not publish

We do not publish forum-derived dosing protocols dressed up as clinical guidance, "before and after" weight-loss photos, anecdotal protocols with no mechanism or evidence base, stack-of-the-month recommendations untethered to a goal profile, or content optimised for a search query that the available evidence cannot honestly support.

We do state each peptide's regulatory status plainly: whether it is FDA-approved, available through compounding, investigational, or sold for research use only. That is a fact about the compound, reported alongside the evidence so you can weigh both. What we do not publish is a ranking that sorts the catalog into better and worse peptides. The engine's internal evidence tiers (FDA-approved, strong clinical, moderate clinical, preclinical, experimental) drive its scoring weights and are not exposed in the protocol output.

9. Update and freshness policy

Posts are scheduled for refresh on a 90-day cycle for top performers and a 180-day cycle by default. Refreshes can also be triggered out-of-cycle by: regulatory changes, new peer-reviewed studies, or recall or safety notices.

Each post surfaces both its original publication date and its most recent review date so readers can judge freshness independently of our schedule. Posts that have aged past their refresh window without an intervening review are flagged internally and routed to the editorial queue; we do not silently leave stale clinical claims in place.

10. Corrections

We correct material errors quickly. If you spot one, write to editorial at klarovel dot com with the post URL and a citation to the corrected fact. Corrections that change a load-bearing claim are noted at the foot of the post; corrections that are purely cosmetic (a typo, a grammar fix) are made silently. The distinction is whether a reader would have acted differently based on the prior version of the claim.

11. Data handling

Users who create a Klarovel account submit a health questionnaire containing data that qualifies as a special category of personal data under GDPR Article 9. We treat that data accordingly: row-level security at the database layer so no user can read another user's questionnaire or protocol; no sharing with advertising networks; no use of the questionnaire data for model training. The full technical and legal treatment is documented in the privacy policy.

12. Contact

Editorial questions: editorial at klarovel dot com. Privacy: privacy policy. Terms: terms of use.